Companies - Pharming

Price

 
Price
€ 1,03
Change
€ 0,01
Change %
0,88%
Open
€ 1,02
High
€ 1,03
Low
€ 1,01
Volume
6.263.721

Profile

 
Profile
Pharming is an innovative biotechnology company that has the mission to create value for all shareholders through the development of therapeutic products for humans. Pharming's goal is the development and commercialization of therapeutic proteins for difficult to treat or non-treatable diseases, thus helping patients and add value for shareholders. The developed applications can be applied in the case of genetic anomalies or use in resolving tissue damage after surgery. The current focus of Pharming is on product innovation. Future growth of the company is pursued through licensing products, its technology and strategic transactions.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2018)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
25,517
Price to Earnings (3 years)
-26,382
Price to Earnings (5 years)
-36,132
Price to earnings growth
-
Price/cashflow
20,211
Price/net cashflow
34,191
Price/book value
-
Price to sales
4,719

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
-
Market value/turnover
4,719
Enterprise value/turnover
4,476

Return ratios

Return on private equity
-
Return on total equity
11,65%
Profit margin
18,49%

Risk ratios

Solvability
-
Solvability
1,000
Current ratio
1,398
Debt to Equity
-

Value invest ratios

Grahams Number
€ -0,16
Grahams Value
€ -1,19
Grahams Product
-
Grahams Product (3 years)
-

2018

 

Profit and loss

Net profit (x 1 mln)
€ 24,99
Turnover (x 1 mln)
€ 135,13
Cashflow(x 1 mln)
€ 31,55
Net cashflow(x 1 mln)
€ 18,65

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
€ 214,57
Current assets (x 1 mln)
€ 115,44
Current liabilities (x 1 mln)
€ 82,60
Working capital (x 1 mln)
€ 32,84
Balance total (x 1 mln)
€ 214,57

Share

Outstanding shares (x 1 mln)
621,500
Price year-end
€ 0,76
Dividend per share
-
Earnings per share
€ 0,04
Cashflow per share
€ 0,05
Net cashflow per share
€ 0,03
Book value per share
-
Stockmarket value (x 1 mln)
€ 470,79

History

 
Year
2018
2017
2016
2015
2014
Net profit (x 1 mln)
€ 24,99
€ -79,96
€ -17,54
€ -9,96
€ -5,77
Turnover (x 1 mln)
€ 135,13
€ 89,62
€ 16,21
€ 10,98
€ 21,29
Price year-end
€ 0,76
€ 1,13
€ 0,22
€ 0,28
€ 0,39
Year high
€ 1,62
€ 1,38
€ 0,32
€ 0,41
€ 0,73
Year low
€ 0,64
€ 0,22
€ 0,15
€ 0,24
€ 0,14
Outstanding shares (x 1 mln)
621,500
579,010
407,687
407,687
407,687
Price to Earnings
18,839
-8,197
-5,044
-11,543
-27,485
Earnings per share
€ 0,04
€ -0,14
€ -0,04
€ -0,02
€ -0,01
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
-
-
€ 27,47
€ 23,84
€ 29,84
PE per share
-
-
€ 0,07
€ 0,06
€ 0,07
Balance total (x 1 mln)
€ 214,57
€ 166,19
€ 126,78
€ 57,68
€ 55,72
Stockmarket value (x 1 mln)
€ 470,79
€ 655,44
€ 88,47
€ 114,97
€ 158,59

Company analysis

 

Analysis of profit indicators

Average profit per share (10 years)
€ -0,17
Standard deviation average profit
€ 0,14 (-83,51%)
Average annual growth rate
-8,42%
Compound annual growth percentage
7,91%
© 2009 - 2020 Skuzet. All Rights Reserved.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.